Zoetis, Inc.
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 07/27/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Zoetis, Inc. |
| Court: | Court: Southern District of New York |
| Case Number: | Case Number: 1:26cv04401 |
| Class Period: | Class Period: 01/14/2025 - 05/06/2026 |
| Ticker: | Ticker: ZTS |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE:ZTS) securities during the period of January 14, 2025 through May 6, 2026, inclusive (“the Class Period”).
The lawsuit alleges that (i) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
On August 2025 that revealed weakening demand trends, slowing veterinarian adoption, intensifying competitive pressures, and declining growth across Zoetis' key Companion Animal franchises. Over the following months, additional disclosures further revealed the extent of the deterioration affecting the Company's core growth products, culminating on May 7, 2026, when Zoetis reported first quarter 2026 financial results reflecting significant deterioration across its Companion Animal business and sharply reduced its full year guidance. On this news, the price of Zoetis shares declined by $23.91 per share, or approximately 22%, from $111.22 per share on May 6, 2026 to close at $87.31 on May 7, 2026.